Is Vandetanib included in medical insurance?

Vandetanib is an oral small molecule targeted drug, mainly a tyrosine kinase inhibitor (TKI). Its original research and development intention is to target multiple key signaling pathways during the growth and metastasis of tumor cells. The drug can simultaneously inhibit the vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and RET kinase signaling pathways. This multiple mechanism of action makes it uniquely valuable in the treatment of specific types of tumors, especially medullary thyroid cancer (MTC;thyroid cancer). Overseas, vandetanib has already been approved by regulatory agencies such as FDA and EMA for the treatment of unresectable, locally advanced or metastatic medullary thyroid cancer, and is clinically considered an important option to improve patients' quality of life and prolong survival.

However, in the Chinese market, vandetanib tablets have not yet been officially launched, and therefore have not been included in the national medical insurance drug list. The core of medical insurance policy is to balance the clinical value of drugs, patient needs and economic accessibility. Only after the drug has completed domestic marketing registration approval, clear indications and passed the medical insurance negotiation process can it be included in the medical insurance system. Since targeted drugs are often more expensive, the financial burden on patients will be very heavy if they are not covered by medical insurance. Therefore, domestic academic circles and patient groups are very concerned about whether vandetanib can be marketed as soon as possible and enter medical insurance.

From a trend perspective, as my country has attached great importance to rare diseases and tumor-targeted drugs in recent years, a number of innovative drugs that have been marketed abroad for many years have been approved domestically. For example,RET inhibitors and multi-target tyrosine kinase inhibitors have gradually entered the market, which shows that domestic approval progress is accelerating. If vandetanib can complete registration approval in the future, it is expected to enter the medical insurance negotiation stage. Once included in medical insurance, it will significantly reduce patient treatment costs and improve drug accessibility.

Reference materials:https://www.drugs.com/caprelsa.html